PMID- 19530993
OWN - NLM
STAT- MEDLINE
DCOM- 20091208
LR  - 20220316
IS  - 2212-4055 (Electronic)
IS  - 1871-5281 (Linking)
VI  - 8
IP  - 2
DP  - 2009 Jun
TI  - Treatment of inflammatory diseases with mesenchymal stem cells.
PG  - 110-23
AB  - Human mesenchymal stem cells (hMSCs) are rare progenitor cells present in adult 
      bone marrow that have the capacity to differentiate into a variety of tissue 
      types, including bone, cartilage, tendon, fat, and muscle. In addition to 
      multilineage differentiation capacity, MSCs regulate immune and inflammatory 
      responses, providing therapeutic potential for treating diseases characterized by 
      the presence of an inflammatory component. The availability of bone marrow and 
      the ability to isolate and expand hMSCs ex vivo make these cells an attractive 
      candidate for drug development. The low immunogenicity of these cells suggests 
      that hMSCs can be transplanted universally without matching between donors and 
      recipients. MSCs universality, along with the ability to manufacture and store 
      these cells long-term, present a unique opportunity to produce an "off-the-shelf" 
      cellular drug ready for treatment of diseases in acute settings. Accumulated 
      animal and human data support MSC therapeutic potential for inflammatory 
      diseases. Several phase III clinical trials for treatment of acute Graft Versus 
      Host Disease (GVHD) and Crohn's disease are currently in progress. The current 
      understanding of cellular and molecular targets underlying the mechanisms of MSCs 
      action in inflammatory settings as well as clinical experience with hMSCs is 
      summarized in this review.
FAU - Newman, Robert E
AU  - Newman RE
AD  - Osiris Therapeutics, Inc., 7015 Albert Einstein Drive, Columbia, MD 21046, USA.
FAU - Yoo, Dana
AU  - Yoo D
FAU - LeRoux, Michelle A
AU  - LeRoux MA
FAU - Danilkovitch-Miagkova, Alla
AU  - Danilkovitch-Miagkova A
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United Arab Emirates
TA  - Inflamm Allergy Drug Targets
JT  - Inflammation & allergy drug targets
JID - 101266886
RN  - 0 (Immunologic Factors)
RN  - 0 (Receptors, Immunologic)
SB  - IM
MH  - Animals
MH  - Cell Differentiation/immunology
MH  - Cell Movement/immunology
MH  - Clinical Trials as Topic
MH  - Crohn Disease/immunology/*therapy
MH  - Graft vs Host Disease/immunology/*therapy
MH  - Histocompatibility
MH  - Humans
MH  - Immunologic Factors/immunology/metabolism
MH  - *Immunosuppression Therapy
MH  - Inflammation
MH  - *Mesenchymal Stem Cell Transplantation
MH  - Mesenchymal Stem Cells/*immunology/metabolism/pathology
MH  - Receptors, Immunologic/immunology/metabolism
MH  - Regeneration
RF  - 103
EDAT- 2009/06/18 09:00
MHDA- 2009/12/16 06:00
CRDT- 2009/06/18 09:00
PHST- 2009/06/18 09:00 [entrez]
PHST- 2009/06/18 09:00 [pubmed]
PHST- 2009/12/16 06:00 [medline]
AID - 10.2174/187152809788462635 [doi]
PST - ppublish
SO  - Inflamm Allergy Drug Targets. 2009 Jun;8(2):110-23. doi: 
      10.2174/187152809788462635.